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is limited in ulcerative colitis in terms of the number of patients and
the length of therapy. Because of their cost advantages, biosimilars
have the potential to improve access to therapy, but physicians have
concerns toward their use because of the lack of evidence from
randomized clinical trials. Objectives: To explore the preferences of
gastroenterologists for biosimilar drugs in ulcerative colitis as well as
to compare our results with results of previous studies on gastro-
enterologists’ preferences toward biosimilars. Methods: A discrete
choice experiment was carried out involving 51 Hungarian gastro-
enterologists treating patients with inﬂammatory bowel disease in
May 2014 with the following attributes: type of treatment (biosimilar/
originator), severity of disease, availability of continuous medicine
supply, and the stopping rule (whether the treatment is covered after
12 months). A conditional logit model was used to estimate theee front matter Copyright & 2016, International S
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.1016/j.vhri.2016.07.004
rest: The authors have indicated that they have n
lacsi@uni-corvinus.hu.
ndence to: László Gulácsi, Department of Health Ecprobabilities of choosing a given proﬁle. Results: According to the
results, the stopping rule was the most important attribute. The type
of treatment mattered only for patients already on biologicals. The
probabilities of choosing the biosimilar option with all the beneﬁts
offered in the discrete choice experiment over the originator option
under the present reimbursement conditions are 85% for new patients
and 63% for patients already treated. Conclusions: Most gastroenter-
ologists have concerns about using biosimilars. They, however, are willing
to consider the use of biosimilars if they could reallocate the potential
savings to provide their patients better access to biological treatment.
Keywords: biologicals, biosimilars, discrete choice experiment,
preferences, ulcerative colitis.
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Biological drugs (such as adalimumab, inﬂiximab, golimumab,
and vedolizumab) are indicated for moderately to severely active
ulcerative colitis (UC) in adult patients who show inadequate
response to conventional therapy (including corticosteroids and
6-mercaptopurine or azathioprine) or who are intolerant to or
have medical contraindications for such therapies [1,2]. Both
induction therapy and maintenance therapy with biological
drugs are highly effective in UC [1–3]. These treatments, however,
are rather costly, and access is rather limited to middle-income
countries. Our previous study shows that in Poland and Bulgaria
biological drugs cover ﬁve chronic inﬂammatory conditions
including Crohn disease (CD) but not for patients with UC [3].
Compared with CD, lower biological treatment rates were found
for UC in many countries such as the United States (16.8%
vs. 3.5%) and most Central and Eastern European countries(0.2%–19.1% vs. 0%–6.4%) [3,4]. In Hungary, only patients with
severe disease activity conditions (with a Mayo score of 4 9) not
responding to conventional therapy including high-dose intra-
venous steroids are eligible for biological treatment. Furthermore,
only 1 year of consecutive therapy is covered by the National
Health Insurance Fund Administration in patients with a clinical
response at week 12 [5], although the literature suggests that the
continuation of treatment after this period would be beneﬁcial
[6,7]. Since 2013, biosimilar inﬂiximab has appeared on the
market, providing a substantially cheaper treatment option for
patients with UC. The biosimilar inﬂiximab drugs (Remsima and
Inﬂectra) are the ﬁrst biosimilar monoclonal antibody medicines
for chronic inﬂammatory conditions approved by the European
Medicines Agency (EMA) in 2013. These drugs were registered
under the same conditions as for the originator inﬂiximab for
the treatment of six adult conditions and in two pediatric
indications [8,9]. Biosimilars offer cost savings and consequentlyociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Nevertheless, randomized clinical trials on its efﬁcacy and safety
have been carried out in only two adult rheumatic disorders
[12,13]. Hence, physicians have concerns about the extension of
indication to inﬂammatory bowel diseases (IBDs) [14,15]. Physi-
cians (as well as payers and patients) therefore face tradeoff
between perceived risks and potential beneﬁts when making
decisions about the use of biosimilar medicines in this indication.
In this case, perceived risk means uncertainty regarding the
outcome of the treatment, also called ambiguity aversion (uncer-
tainty aversion) in unknown.
In our study, we have carried out a discrete choice experiment
(DCE) among gastroenterologists to reveal clinicians’ preferences
for originator versus biosimilar treatment in UC. The choice task
described hypothetical scenarios, in which some beneﬁts with
regard to access to biological treatment (e.g., to start the treat-
ment in less severe conditions, the availability of continuous
medicine supply, and to continue treatment after 12 months)
are offered when using the biosimilar treatment option. We
are particularly interested whether these preferences are
different in UC and in other conditions such as CD. The study
aimed to provide important evidence on clinicians’ preferences,
which might affect the penetration of biosimilars into
clinical practice and therefore the potential beneﬁts related to
their use.
This research is a part of a study that focused on gastro-
enterologists’ preferences for using biosimilars for IBD. Results
for CD have already been published elsewhere [16]. This article
presents the results for UC.Table 1 – Example for a choice set.
Attribute Type of treatment
Originator Biosimilar
Indication Can be applied for
patients with a
Mayo score of 49
Can be applied for
patients with a
Mayo score of 49
Supply of
medicines
Because of a shortage
of medicines, the
treatment can be










the 12 mo ifMethods
Questionnaire
The study design and the process of data collection have already
been described in detail elsewhere [16], but we will provide a brief
description here.
A DCE is a widely used stated-preference method to evaluate
preferences [17–19]. In a DCE, respondents are faced with a
hypothetical scenario and choice sets of treatment options (goods
or services) described by different attributes. The proﬁles differ
from each other in the levels of their attributes. In all the choice
sets, the respondents are asked to choose the proﬁle that they
prefer the most.
In our DCE, gastroenterologists treating patients with IBD
were asked to imagine a hypothetical scenario in which budget
savings of biosimilars were spent to provide patients better
access to biological treatment. Seven hypothetical choice sets of
two treatment options were presented, and respondents were
asked to choose the one they preferred. All the choice sets
contained a base-case originator treatment option under the
present reimbursement conditions as well as an alternative
biosimilar option in which various beneﬁts providing better
access to treatment were offered.
The following attributes describing better access to biological
treatment were selected on the basis of interviews with experts:necessary
For new patients:1.
1. I start the therapy with the originator agent.
2. I start the therapy with the biosimilar treatment if I ﬁnd the
situation appropriate.
For treated patients:
1. I continue to use the originator agent.Milder disease severity prerequisite for the initiation of biological
treatment: At present, patients with UC with a Mayo score of 9
or less are not entitled for reimbursed biological treatment.
Experts argue that starting the biological treatment at a lower
disease activity level would result in a potential beneﬁt of less
costly treatment options.2. I change from the originator therapy to the biosimilar treatment2.
if I ﬁnd the situation appropriate.Availability of continuous medicine supply: Clinicians mentioned
budget constraints as a problem for the present medicine
supply, which can lead to delays in the treatment.3. Stopping rule: According to the present reimbursement guide-
line, the treatment can be continued beyond 12 weeks only if
patients show clinical response or reach clinical remission,
and should be stopped after 12 months of consecutive bio-
logical therapy regardless of the response. After 1 year of
treatment, patients have to be switched to the conventional
therapy. Anti–tumor necrosis factor drugs can be restarted
only in case of a ﬂare-up.
Thus, the base scenario described the originator treatment
under the present reimbursement conditions (i.e., can be applied
if the Mayo score is 9 or more, treatment might be delayed by 3–4
weeks because of the lack in supply of medicines, and treatment
cannot be continued after 12 months). The following alternative
biosimilar scenarios described the seven possible combinations
of potential beneﬁts on access to treatment: 1) can already be
applied for patients with a Mayo score of more than 6, 2)
continuous medicine supply is available, and 3) the treatment
does not have to be stopped after 12 months.
In the seven choice sets, clinicians were asked to choose the
preferred treatment option for 1) biological-naive patients and 2)
patients currently treated with the originator biological drug.
Table 1 presents an example for a choice set. The questionnaire
was piloted with ﬁve clinicians.
The questionnaire contained additional questions regarding
sociodemographic and professional features of the gastroenter-
ologists and their practices. A multiple-choice question regarding
clinicians’ attitude to biosimilar treatment was also included in
the questionnaire with the following options: 1) have no concerns
about the use of biosimilar medicines in UC, and these can be
applied under the same conditions as the originator; 2) have
some concerns about using biosimilars; and 3) biosimilar medi-
cines should not be applied in UC at all. For those who indicated
concerns, we wanted to get a better insight into the origin of their
perceived risk, and therefore they were asked whether these
concerns are related to efﬁcacy, safety, both efﬁcacy and safety,
or any other reason.
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The study was carried out in Hungary where biosimilar inﬂiximab
has been covered by the National Health Insurance Fund for the
treatment of UC since May 2014. Data were collected among
gastroenterologists during a meeting of the Hungarian Gastro-
enterology Society in May 2014. Altogether 200 questionnaires
were distributed. The participation was voluntary, and informed
consent was taken. Ethical approval was obtained (Semmelweis
University Regional and Institutional Committee of Science and
Research Ethics, No. 103/2014). The study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki
(6th revision, 2008) as reﬂected in a priori approval by the
institution’s human research committee.
Data Analysis
A conditional logit model was used to analyze the DCE. The
relative importance of the attributes was estimated. Odds ratios
(ratio of the probability of choosing the alternative biosimilar
proﬁle over the probability of choosing the base originator option)
are presented. A separate analysis was carried out for biological-
naive patients and patients already treated with the originator.Results
Fifty-one gastroenterologists ﬁlled in the survey (65% women)
with the average age of 47.6 years (range 26–74 years). Other
sociodemographic and professional characteristics of physicians
are presented in Table 2. Regarding their attitudes toward
biosimilar drugs, 10 clinicians (19.6%) indicated that they have
absolutely no concerns regarding using biosimilars in UC, as the
EMA registered them under the same conditions as the origina-
tors. Thirty-four (66.7%) clinicians indicated some concerns about
using biosimilars in UC (2 had concerns about efﬁcacy, 5 had
concerns about safety, and 24 had concerns with both efﬁcacy
and safety). Six (11.8%) clinicians said they do not support the use
of biosimilars in UC at all because of the lack of evidence from
randomized controlled trials in this indication. One respondent
did not answer this question.
In the DCE, 84% of the respondents chose the biosimilar
option in at least one of the choice sets for biological-naive
patients, and 61% for patients already treated with biologicals.
Even among those who indicated concerns related to biosimilars,
these shares were 80% and 53%, respectively.
The estimated coefﬁcients of the conditional logit model are
presented in Table 3. According to the results, the stopping rule
(i.e., whether the continuation of treatment after 12 months is
reimbursed) was found to be the most important treatment
attribute driving the choices for both biological-naive patients
and patients already treated with biologicals. For biological-naive
patients, this was followed by the severity of the disease and the
frequency of efﬁcacy checkups. The type of treatment (biosimilar
or originator) was found not to be a signiﬁcant determinant of
choice for biological-naive patients. For patients already treated
with biologicals, the type of treatment (biosimilar or originator)
was the second most important factor (preferring the originator
treatment), followed by the continuity of the medicine supply.
Severity had a positive but insigniﬁcant coefﬁcient.
Predicted probabilities of choosing biosimilar medicines over
the originator treatment under the present reimbursement con-
ditions (i.e., can be applied when the Mayo score is49, treatment
might be delayed by 3–4 weeks because of the lack in supply of
medicines, and the treatment cannot be continued after 12
months) were calculated (see Table 3). For new patients, the
estimated probability of choosing the originator treatment over
the biosimilars, when all the attributes describe the presentreimbursement situation, is 48%. For patients already treated
with biologicals, this probability is higher (71%). The probability of
choosing the biosimilars with all the beneﬁts offered over the
originator treatment in the present situation is 85% versus 15%
for new patients and 63% versus 37% for patients already treated
with biologicals.Discussion
A DCE was carried out to study the treatment preferences of
gastroenterologists for biosimilar versus originator drugs in UC.
We were particularly interested whether certain beneﬁts with
regard to access to biological treatment might compensate for the
perceived risks of using biosimilars (e.g., uncertainty related to
lack of experience). The study was part of a larger survey that
assessed gastroenterologists’ preferences regarding biosimilars in
CD and UC [16].
Most of the gastroenterologists (78%) had concerns regarding
the use of biosimilars in UC, but they were willing to consider
biosimilar treatment options if certain beneﬁts providing better
access to biological therapy were offered in exchange. According
to the results, one of the major beneﬁts of biosimilars would be if
the treatment of patients would not be discontinued after 12
months, but the continuity of the medical supply was also an
important beneﬁt. These could compensate for the perceived risk
of using biosimilar treatment for both new patients (biological-
naive) and patients already treated with biologicals.
In the other section of this study on CD, we also found that
the same gastroenterologists had similar concerns with biosimi-
lars in CD and UC, and in both studies they were more willing to
consider the biosimilar treatment option for new patients than
for patients already treated with biologicals [16]. In UC, however,
physicians were more willing to use the biosimilar treatment
than in CD for patients already treated with biologicals. The
probability of choosing the biosimilar option with all the beneﬁts
offered over the originator treatment option with the present
reimbursement guideline was 44% versus 56% for patients
already treated with biologicals. In this study, this probability
was 63% versus 37%. This difference is most probably because in
CD the biological treatment is not to be discontinued after 12
months.
So far, only a few studies have reported about physicians’
concerns toward biosimilars in IBD and in rheumatic conditions
[14,15]. Our study offers a different methodology, namely, DCE,
which is although hypothetical, but makes the clinicians “trade”
between beneﬁts and perceived risks of biosimilars. Regarding
the questions on attitude in our study, 78% of the clinicians
indicated concerns or were against the use of biosimilars in UC.
In the DCE, however, 84% of the respondents chose the biosimilar
option in at least one of the choice sets for new patients and 61%
for patients already treated with biologicals. This suggests that
beneﬁts related to access are highly valued by clinicians and
could be an effective tool to increase the attractiveness of
biosimilars among clinicians. It should be highlighted that we
examined a hypothetical scenario in which budget savings
remained in the clinicians’ praxis and were spent to provide
their patients better access to treatment. In real life, however, it
might not be the case. Thus, physicians might be less motivated
to use biosimilars.
Perceived risk means some kind of uncertainty regarding the
outcome of the treatment, often called ambiguity aversion
(uncertainty aversion) in unknown. In this case, we can distin-
guish between individual patient-level and society-level out-
come. In this survey, we asked gastroenterologists very directly
about their fears regarding the outcome on the individual patient
level (questions on efﬁcacy and safety of biosimilars compared
Table 2 – Descriptive statistics of the sample.
Variable n (%) Mean  SD Range (min.–max.)
Clinicians’ characteristics
Age (y) 51 (100) 47.6  11.4 26–74
Years of practice as a specialized gastroenterologist 48 (94.1) 19.0  11.3 0*–45
Sex: female 33 (64.7) – –
Senior consultant 21 (41.2) – –
Scientiﬁc committee member 21 (41.2) – –
PhD 28 (54.9) – –
Practice
Settlement of practice – –
Budapest 21 (41.2)
County capital 23 (45.1)
Other town/city 4 (7.8)
Multiple 3 (5.9)
Type of practice – –
Outpatient care 5 (9.8)
Inpatient care 21 (41.2)
Both 24 (47.1)
Missing 1 (2.0)
Practice: mainly hepatology 5 (9.8) – –
Practice: mainly gastroenterology 33 (64.7) – –
Practice: mainly IBD 19 (37.3) – –
IBD centrum 33 (64.7) – –
Number of patients with UC 50 (98.0) 23.5  26.0 0–100
Number of patients with UC treated with biologicals 50 (98.0) 3.4  5.3 0–20
Risk perception regarding the use of biosimilars in UC – –
No concerns 10 (19.6)
Concerns regarding the safety or efﬁcacy 34 (66.7)
Should not be applied because of lack of RCTs in UC 6 (11.8)
Missing 1 (2.0)
IBD, inﬂammatory bowel disease; max., maximum; min., minimum; RCTs, randomized clinical trials; UC, ulcer colitis.
* During specialization training.
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growing literature regarding real-world evidence for biosimilars
[20,21]. We assume that this will prove the validity of the EMA’s
standpoint such that there is no difference between inﬂiximab
and biosimilar inﬂiximab in terms of efﬁcacy and safety, and thus
physicians’ ambiguity aversion in unknown is supposed to
decrease. Societal outcomes are always more complex and
difﬁcult to assess and till date there is a lack of cost-
effectiveness studies in the literature on biosimilars in UC that
could inform clinicians about the expected changes in costs and
outcomes on the societal level. Our DCE results, however, reﬂect
that gastroenterologists take into consideration broader aspects
than only the individual patient angle. Attributes that would
close the gap between the clinical and ﬁnancial guidelines were
highly rated by physicians, because these could improve UC care,
and as a consequence could beneﬁt not only the individual
patients but also the society. Reallocating budget savings, pref-
erably among patients with IBD, provides additional beneﬁt
(health gain) at the societal level. Both types of information seem
to reduce physicians’ uncertainty regarding the outcome of the
treatment.
In Hungary since May 2014, “newly initiated biological therapy
with inﬂiximab must be undertaken with a biosimilar drug” to be
reimbursed by the social health insurance. The issue of inter-
changeability is not addressed in the ﬁnancial guideline [3]. Thus,
the present practice might have an inﬂuence on preferences as
well. Nevertheless, we highlighted in the questionnaire that we
examined hypothetical scenarios, and speciﬁcally asked clini-
cians to imagine that they had the authority to decide about theuse of biosimilars. Furthermore, we have to account for the
potential of sample selection bias. The relatively low sample size
might limit the robustness of the statistical analysis. There are,
however, only 16 IBD biological centers in Hungary [3], and the
number of IBD specialists prescribing biologicals is approximately
50 to 60. In our study, most of the respondents (65%) were such
specialists from IBD biological centers. At the national congress,
we distributed the questionnaire to available gastrointestinal
specialists, many of whom do not treat IBDs regularly and are
interested in therapeutic endoscopy/hepatology. From the
responses we received (65% working in IBD/biological centers),
it was clear that responses were mainly obtained from the
specialists who indeed prescribe and use the biologicals. Thus,
the target group of specialists is well represented and we believe
that the responses are representative for the doctors who are
active in IBD care in the country.Conclusions
Our study provides important evidence on the preferences of
clinicians using biosimilars in UC. It is essential to study and be
aware of these preferences, because these directly or indirectly
inﬂuence treatment practices and choice of medication, and
consequently the budget impact of biosimilars. We found that
even though most gastroenterologists have concerns regarding
the use of biosimilars, they are willing to consider treatment
options with biosimilars if better access to biological treatment is
provided in exchange.
Table 3 – Results of the conditional logit model and predicted probabilities of choosing biosimilar medicine over the originator treatment under the
present reimbursement conditions.















New patients, coefﬁcient (SE) 0.0931 (0.305) 0.526* (2.958) 0.526* (2.875) 0.624* (3.457) 714 19.36 (P o 0.001) 0.184
Treated patients, coefﬁcient (SE) –0.899* (3.292) 0.0903 (1.183) 0.260* (2.690) 1.062* (4.459) 714 26.01 (P o 0.001) 0.047
Estimated probabilities
Scenario Type: biosimilar Beneﬁt New patients Treated patients
Less severe condition Secure supply No stopping rule Pr† (%) OR ¼ Pr(alt)/Pr(base) Pr† (%) OR ¼ Pr(alt)/Pr(base)
Base scenario No No No No
Biosimilar scenario 1 Yes No No No 52 1.10 29 0.35
Biosimilar scenario 2 Yes Yes No No 65 1.86 31 0.39
Biosimilar scenario 3 Yes No Yes No 65 1.86 35 0.74
Biosimilar scenario 4 Yes No No Yes 67 2.05 54 0.35
Biosimilar scenario 5 Yes Yes Yes No 76 3.14 37 0.82
Biosimilar scenario 6 Yes Yes No Yes 78 3.47 60 0.73
Biosimilar scenario 7 Yes No Yes Yes 78 3.47 56 0.38
Biosimilar scenario 8 Yes Yes Yes Yes 85 5.87 63 0.80
OR, odds ratio; Pr, probability; SE, standard error.
* P o 0.001.
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